Start Date
September 12, 2023
Primary Completion Date
August 5, 2024
Study Completion Date
August 5, 2024
Palbociclib Oral Product
125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
TAS-116
120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
TAS-116
80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
TAS-116
40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
Lifespan Cancer Institute, Providence
Lead Sponsor
Brown University
OTHER